 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C33H54F3N9O8 |
| Molecular Weight | 761.83257818222 |
| Exact Mass | 761.404 |
| CAS # | 1313730-19-6 |
| Related CAS # | TFLLR-NH2;197794-83-5 |
| PubChem CID | 71311619 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 20 |
| Heavy Atom Count | 53 |
| Complexity | 1110 |
| Defined Atom Stereocenter Count | 6 |
| SMILES | C(F)(F)(F)C(=O)O.[C@@H](NC(=O)[C@@H](N)[C@H](O)C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N)CCCNC(N)=N)CC1C=CC=CC=1 |
| InChi Key | QVNWOGSDGQDGHP-MKVNCOEFSA-N |
| InChi Code | InChI=1S/C31H53N9O6.C2HF3O2/c1-17(2)14-22(27(43)37-21(26(33)42)12-9-13-36-31(34)35)38-28(44)23(15-18(3)4)39-29(45)24(16-20-10-7-6-8-11-20)40-30(46)25(32)19(5)41;3-2(4,5)1(6)7/h6-8,10-11,17-19,21-25,41H,9,12-16,32H2,1-5H3,(H2,33,42)(H,37,43)(H,38,44)(H,39,45)(H,40,46)(H4,34,35,36);(H,6,7)/t19-,21+,22+,23+,24+,25+;/m1./s1 |
| Chemical Name | (2S)-N-[(2S)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide;2,2,2-trifluoroacetic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | PAR1 agonists cause concentration-dependent increases in [Ca2+]i and neuronal ratios. In response to 10 μ m TF-NH2, 50–80% of the identified neurons showed the greatest increase in [Ca2+]i above basal values (peak 196.5±20.4 nM, n=25) [1]. Expression of E-cadherin was upregulated and vimentin was downregulated in SW620 cells cultured in TFLLR-NH2 activated platelet supernatants. A dose-dependent rise in TGF-β1 secreted by TFLLR-NH2 was found in the supernatant of an in vitro platelet culture system [2]. |
| ln Vivo | Rat paws were injected with TF-NH2, which caused a notable and long-lasting edema. Capsaicin and NK1R antagonist-induced sensory nerve ablation reduced edema by 44% in 1 hour and by 100% in 5 hours. TF-NH2 increased Evans blue extravasation 2- to 8-fold in the bladder, esophagus, stomach, intestine, and pancreas in wild-type mice, but not in PAR1−/− animals. Extravasation in the stomach, esophagus, and bladder can be completely eliminated by NK1R antagonists [1]. TFp-NH2 induced considerable contraction at 3-50 μM and significant relaxation at 0.3-50 μM in the absence of apamin. The concentration-response curve of TFp-NH2-induced contraction markedly moved to the left when 0.1 μM apamin inhibited TFp-NH2-induced relaxation [3]. |
| References |
[1]. Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol. 2001 Aug;133(7):975-87. [2]. Characterization of the protease-activated receptor-1-mediated contraction and relaxation in the rat duodenal smooth muscle. [3]. Activation of platelet protease-activated receptor-1 induces epithelial-mesenchymal transition and chemotaxis of colon cancer cell line SW620. Oncol Rep. 2015 Jun;33(6):2681-8. |
Solubility Data
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~131.26 mM) DMSO : ~100 mg/mL (~131.26 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 33.33 mg/mL (43.75 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3126 mL | 6.5631 mL | 13.1263 mL | |
| 5 mM | 0.2625 mL | 1.3126 mL | 2.6253 mL | |
| 10 mM | 0.1313 mL | 0.6563 mL | 1.3126 mL |